deferoxamine

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.

Deferoxamine-DBCO is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DFO derivative employed in tumor pre-targeting. It is applicable for the conjugation of peptides and radionuclides.

Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

Mal-Deferoxamine is a maleimide-functionalized derivative of Deferoxamine in which the maleamide group enables highly selective and covalent conjugation with thiol-containing biomolecules, forming stable linkages suited for chemical biology and radiopharmaceutical engineering. Mal-Deferoxamine readily chelates medical radionuclides to generate radionuclide drug conjugates (RDCs), which permit targeted molecular imaging or therapeutic delivery owing to their ability to engage specific biomolecular targets with high affinity, making this compound a versatile scaffold for the development of diagnostic probes and radiotheranostic agents.

Erastin2 is a ferroptosis inducer and inhibitor of the system xc- cystine/glutamate transporter.[1][2] It inhibits glutamate release in CCF-STTG1 cells (IC50 = 0.0035 µM) and induces cell death in HAP1 cells at 5 µM, an effect blocked by ferrostatin-1 or deferoxamine.[1][2] Erastin2 also induces ferroptotic cell death in HT-1080 cells (EC50 = 0.15 µM), an effect blocked by β-mercaptoethanol (EC50 > 20 µM).[3] Additionally, it increases lipid peroxidation in HT-1080 cells at 1 µM.